Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the aetiological agent of
coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by the …

The pharmaceutical industry has been desperately searching for efficient drug discovery
methods. Organ-on-a-Chip, a cutting-edge technology that can emulate the physiological …

A newly described coronavirus named severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has …

To date, seven identified coronaviruses (CoVs) have been found to infect humans; of these,
three highly pathogenic variants have emerged in the 21st century. The newest member of …

Following the advancements in microfluidics and lab-on-a-chip (LOC) technologies, a novel
biomedical application for microfluidic based devices has emerged in recent years and …

Summary Coronavirus disease 2019 (COVID-19) is the latest respiratory pandemic caused
by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). Although …

Rapid development of vaccines and therapeutics is necessary to tackle the emergence of
new pathogens and infectious diseases. To speed up the drug discovery process, the …

The failure rate for the translation of drugs from animal testing to human treatments remains
at over 92%, where it has been for the past few decades. The majority of these failures are …

Mechanical breathing motions have a fundamental function in lung development and
disease, but little is known about how they contribute to host innate immunity. Here we use a …

While conventional in vitro culture systems and animal models have been used to study the
pathogenesis of viral infections and to facilitate development of vaccines and therapeutics …